Advertisement

Medical Oncology

, Volume 29, Issue 5, pp 3147–3154 | Cite as

Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients

  • Emin Tamer ElkiranEmail author
  • Mehmet Ali Kaplan
  • Alper Sevinc
  • Sercan Aksoy
  • Umut Demirci
  • Mesut Seker
  • Hakan Harputluoglu
  • Nuriye Yildirim Ozdemir
  • Feridun Isik
  • Arife Ulas
  • Mevlude Inanc
  • Ulku Yalcintas Arslan
  • Gamze Gokoz Dogu
  • Abdurrahman Isikdogan
  • Suleyman Buyukberber
  • Anatolian Society of Medical Oncology Group
Original Paper

Abstract

Malignant pleural mesothelioma (MPM) is a relatively rare, but aggressive tumor that causes high mortality. The major risk factor involved in the etiology is environmental and occupational exposure to asbestos. The optimal modality of therapy is controversial. The present study retrospectively evaluated the data pertinent to 282 patients who were examined and treated in 11 different medical oncology centers in Turkey. There were 161 males (57.1 %) and 121 females (42.9 %), with a mean age of 56.38 ± 12.07 years. Surgery was used in 74 patients, 21 patients (28.4 %) received only chemotherapy and 28 patients (37.8 %) received chemoradiotherapy after surgery. The median survival in patients who were administered adjuvant therapy after surgery was 24 months, while the median survival in patients who had only surgery was 6 months (p = 0.029). 106 patients were administered pemetrexed-platinum combination and 35 patients were administered gemcitabine-platinum combination as front-line chemotherapy. Median survival, 1- and 2-year survival rates in patients who received platinum analogues and pemetrexed or gemcitabine combinations were found statistically similar (p = 0.15). The median survival for all patients with MPM in our study was 18 months. The main factors influencing the overall survival were stage of the disease (p = 0.020), performance status (p < 0.001), asbestos exposure (p = 0.030) and mesothelioma histological subtypes (p < 0.001). Results of our study suggest that multi-modality treatment regimens consisting of surgery, radiotherapy and chemotherapy prolong overall survival. Survival rates in patients who received combining platinum analogues with pemetrexed or gemcitabine as front-line chemotherapy were found similar.

Keywords

Malignant pleural mesothelioma Asbestos exposure Multi-modality treatment Front-line chemotherapy Prognostic factors 

Notes

Acknowledgments

This manuscript was not supported by any financial help or other relationships.

References

  1. 1.
    Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576–88.PubMedCrossRefGoogle Scholar
  2. 2.
    Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397–408.PubMedCrossRefGoogle Scholar
  3. 3.
    Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol. 2002;26:55–65.PubMedCrossRefGoogle Scholar
  4. 4.
    Wagner JC. Mesothelioma and mineral fibers. Cancer. 1986;57:1905–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Selcuk ZT, Coplu L, Emri S, Kalyoncu AF, Sahin AA, Baris YI. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest. 1992;102:790–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Selcuk ZT, Emri S, Sahin AA, Baris YI, Coplu L, Kalyoncu F, et al. Malignant mesothelioma and erionite exposure. Eur Respir J. 1999;14:480–1.PubMedGoogle Scholar
  7. 7.
    Baris YI. Fibrous zeolite (erionite)-related diseases in Turkey. Am J Ind Med. 1991;19:374–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Sugarbaker DJ, Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest. 1998;113:61S–5S.PubMedCrossRefGoogle Scholar
  9. 9.
    Neumeister W, Gillissen A, Rasche K, Theile A, Muller KM, Schultze-Werninghaus G. Prognosis, staging and therapy of malignant pleural mesothelioma. Med Klin (Munich). 2002;97:459–71.CrossRefGoogle Scholar
  10. 10.
    Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur Respir J. 1998;12:972–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Kaufman AJ, Pass HI. Current concepts in malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2008;8:293–303.PubMedCrossRefGoogle Scholar
  12. 12.
    Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008;371:1685–94.PubMedCrossRefGoogle Scholar
  13. 13.
    Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol. 1988;6:147–53.PubMedGoogle Scholar
  14. 14.
    Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995;108:1122–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Metintas M, Ozdemir N, Hillerdal G, Ucgun I, Metintas S, Baykul C, et al. Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med. 1999;93:349–55.PubMedCrossRefGoogle Scholar
  17. 17.
    Yazicioglu S. Pleural calcification associated with exposure to chrysotile asbestos in southeast Turkey. Chest. 1976;70:43–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Muller KM, Fischer M. Malignant pleural mesotheliomas: an environmental health risk in southeast Turkey. Respiration. 2000;67:608–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Senyigit A, Bayram H, Babayigit C, Topcu F, Nazaroglu H, Bilici A, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. Respiration. 2000;67:615–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Barıs YI, Artvinli M, Sahin AA. Environmental mesothelioma in Turkey. Ann NY Acad Sci. 1980;330:423–32.CrossRefGoogle Scholar
  21. 21.
    Metintas M, Hillerdal G, Metintas S. Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J. 1999;13:523–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Dumortier P, Gocmen A, Laurent K, Manco A, De Vuyst P. The role of environmental and occupational exposures in Turkish immigrants with fibre-related disease. Eur Respir J. 2001;17:922–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Baris I, Simonato L, Artvinli M, Pooley F, Saracci R, Skidmore J, et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer. 1987;39:10–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Emri S, Demir A, Doğan M. Lung diseases due to environmental exposures to erionite and asbestos in Turkey. Toxicol Lett. 2002;127:251–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Artvinli M, Baris YI. Environmental fiber-induced pleuro-pulmonary diseases in an Anatolian village: an epidemiologic study. Arch Environ Health. 1982;37:177–81.PubMedGoogle Scholar
  26. 26.
    Sakellariou K, Malamou-Mitsi V, Haritou A, Koumpaniou C, Stachouli C, Dimoliatis ID, et al. Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic? Eur Respir J. 1996;9:1206–10.PubMedCrossRefGoogle Scholar
  27. 27.
    Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev. 1997;6:162–6.PubMedGoogle Scholar
  28. 28.
    Baris YI, Bilir N, Artvinli M, Sahin AA, Kalyoncu F, Sebastien P. An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos. Br J Ind Med. 1988;45:838–40.PubMedGoogle Scholar
  29. 29.
    Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest. 2002;122:2224–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Senyigit A, Babayigit C, Gokirmak M, Topcu F, Asan E, Coskunsel M, et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration. 2000;67:610–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Schwartz DA. New developments in asbestos-induced pleural disease. Chest. 1991;99:191–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: review of 123 patients. Cancer. 1982;49:2431–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer. 1993;72:394–404.PubMedCrossRefGoogle Scholar
  34. 34.
    Kurt B, Gülhan M, Apaydın Z, Ark D. Malignant pleural mesothelioma: a retrospective analysis of 57 cases. ERJ 1997;(Suppl 25):199.Google Scholar
  35. 35.
    Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax. 1997;52:507–12.PubMedCrossRefGoogle Scholar
  36. 36.
    Pisani RJ, Colby TV, Williams DE. Malignant mesothelioma of the pleura. Mayo Clin Proc. 1988;63:1234–44.PubMedGoogle Scholar
  37. 37.
    Sovak MA, Aisner SC, Aisner J. Tumors of the pleura and mediastinum. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Abeloff’s clinical oncology, vol. 4. Philadelphia: Churchill Livingstone; 2008. p. 1367–90.CrossRefGoogle Scholar
  38. 38.
    Hillerdal G. Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest. 1983;77:321–43.PubMedCrossRefGoogle Scholar
  39. 39.
    Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest. 2004;125:1103–17.PubMedCrossRefGoogle Scholar
  40. 40.
    Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111:106–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc. 1985;60:158–64.PubMedGoogle Scholar
  42. 42.
    Herbert A, Gallagher PJ. Pleural biopsy in the diagnosis of malignant mesothelioma. Thorax. 1982;37:816–21.PubMedCrossRefGoogle Scholar
  43. 43.
    Whitaker D, Shilkin KB. Diagnosis of pleural malignant mesothelioma in life–a practical approach. J Pathol. 1984;143:147–75.PubMedCrossRefGoogle Scholar
  44. 44.
    Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest. 2004;126:1318–29.PubMedCrossRefGoogle Scholar
  45. 45.
    Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, Bernatz PE. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer. 1986;58:1540–51.PubMedCrossRefGoogle Scholar
  46. 46.
    Segal A, Whitaker D, Henderson D, Shilkin K. Pathology of mesothelioma. In: Robinson BWS, Chahinian AP, editors. Mesothelioma. London: Martin Dunitz; 2002. p. 143–84.Google Scholar
  47. 47.
    Tammilehto L, Maasilta P, Kostiainen S, Appelqvist P, Holsti LR, Mattson K. Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients. Respiration. 1992;59:129–35.PubMedCrossRefGoogle Scholar
  48. 48.
    Butchart EG. Contemporary management of malignant pleural mesothelioma. Oncologist. 1999;4:488–500.PubMedGoogle Scholar
  49. 49.
    Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits? Chest. 1995;107:345S–50S.PubMedCrossRefGoogle Scholar
  50. 50.
    Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol. 2007;4:344–52.PubMedCrossRefGoogle Scholar
  51. 51.
    Buduhan G, Menon S, Aye R, Louie B, Mehta V, Vallieres E. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2009;88:870–5. (discussion 6).PubMedCrossRefGoogle Scholar
  52. 52.
    Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63. (discussion 5).PubMedCrossRefGoogle Scholar
  53. 53.
    Lucchi M, Chella A, Melfi F, Dini P, Ambrogi M, Fino L, et al. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2007;31:529–33. (discussion 33–34).PubMedCrossRefGoogle Scholar
  54. 54.
    Sorensen JB. Current concepts in chemotherapy for malignant pleural mesothelioma. Clin Respir J. 2008;2:74–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002;38:111–21.PubMedCrossRefGoogle Scholar
  56. 56.
    Ardizzoni A, Grossi F, Pennucci MC. Systemic drug therapy of malignant pleural mesothelioma. Monaldi Arch Chest Dis. 1998;53:236–40.PubMedGoogle Scholar
  57. 57.
    Santoro A, O’Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3:756–63.PubMedCrossRefGoogle Scholar
  58. 58.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.PubMedCrossRefGoogle Scholar
  59. 59.
    Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25–30.PubMedGoogle Scholar
  61. 61.
    Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol. 2005;28:223–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Favaretto AG, Aversa SM, Paccagnella A, Manzini VP, Palmisano V, Oniga F, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer. 2003;97:2791–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Lee C, Murray N, Anderson H, Bouttell E. Outcomes with platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice. J Thorac Oncol. 2007;2:606.CrossRefGoogle Scholar
  64. 64.
    Metintas M, Metintas S, Ucgun I, Gibbs AR, Harmanci E, Alatas F, et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med. 2001;95:829–35.PubMedCrossRefGoogle Scholar
  65. 65.
    Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145–52.PubMedGoogle Scholar
  66. 66.
    Borasio P, Berruti A, Bille A, Lausi P, Levra MG, Giardino R, et al. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg. 2008;33:307–13.PubMedCrossRefGoogle Scholar
  67. 67.
    Chailleux E, Dabouis G, Pioche D, de Lajartre M, de Lajartre AY, Rembeaux A, et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest. 1988;93:159–62.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Emin Tamer Elkiran
    • 1
    Email author
  • Mehmet Ali Kaplan
    • 2
  • Alper Sevinc
    • 3
  • Sercan Aksoy
    • 4
  • Umut Demirci
    • 5
  • Mesut Seker
    • 6
  • Hakan Harputluoglu
    • 1
  • Nuriye Yildirim Ozdemir
    • 4
  • Feridun Isik
    • 7
  • Arife Ulas
    • 8
  • Mevlude Inanc
    • 9
  • Ulku Yalcintas Arslan
    • 10
  • Gamze Gokoz Dogu
    • 11
  • Abdurrahman Isikdogan
    • 2
  • Suleyman Buyukberber
    • 5
  • Anatolian Society of Medical Oncology Group
  1. 1.Department of Medical Oncology, Faculty of MedicineInonu UniversityMalatyaTurkey
  2. 2.Department of Medical Oncology, Faculty of MedicineDicle UniversityDiyarbakirTurkey
  3. 3.Department of Medical Oncology, Faculty of MedicineGaziantep UniversityGaziantepTurkey
  4. 4.Department of Medical OncologyAnkara Numune Education and Research HospitalAnkaraTurkey
  5. 5.Department of Medical Oncology, Faculty of MedicineGazi UniversityAnkaraTurkey
  6. 6.Department of Medical OncologyDr. Lutfi Kirdar Kartal Education and Research HospitalIstanbulTurkey
  7. 7.Departments of Thoracic Surgery, Faculty of MedicineGaziantep UniversityGaziantepTurkey
  8. 8.Department of 1st Medical OncologyAnkara Oncology Research and Training HospitalAnkaraTurkey
  9. 9.Department of Medical Oncology, Faculty of MedicineErciyes UniversityKayseriTurkey
  10. 10.Department of 2nd Medical OncologyAnkara Oncology Training and Research HospitalAnkaraTurkey
  11. 11.Department of Medical Oncology, Faculty of MedicinePamukkale UniversityDenizliTurkey

Personalised recommendations